{"id":330273,"date":"2026-10-28T12:36:34","date_gmt":"2026-10-28T07:06:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=330273"},"modified":"2026-10-28T12:36:34","modified_gmt":"2026-10-28T07:06:34","slug":"generic-formulations-maker-latin-america-branded-generics-seller-and-leading-chronic-therapy-pharma-company-stocks-roadmap-nimbus-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/generic-formulations-maker-latin-america-branded-generics-seller-and-leading-chronic-therapy-pharma-company-stocks-roadmap-nimbus-list\/","title":{"rendered":"3 Generic Formulations Maker, Latin America Branded Generics Seller and Leading Chronic Therapy Pharma Company Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals"},"content":{"rendered":"

Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals: ROE of 11.9% to 25.5% and FY22 to FY26 revenue CAGR of 8.4% to 15.2%. Prices as of 27 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The three chronic therapy and generic formulation stocks to watch are Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals. Their return on equity ranges from 11.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 15.2%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Caplin Point Laboratories has the fastest revenue growth at 15.2% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n

Chronic therapy and generic formulation stocks offer a focused view of a sector where demand keeps widening. Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals cover a generic formulations maker, a Latin America focused branded generics seller and a leading chronic therapy pharma company.<\/p>\n

This list covers three chronic therapy and generic formulation stocks with complete current figures: Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n